Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Complement System01:27

Complement System

12.2K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
12.2K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

86.0K
Overview
86.0K
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

115
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
115
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.9K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.9K
Antibody Actions01:26

Antibody Actions

3.5K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Type 2 and type 1 diabetes have opposing effects on the systemic murine complement alternative pathway.

iScience·2026
Same author

C4BP occludes the non-opsonic interaction of <i>Neisseria gonorrhoeae</i> with human neutrophil CEACAMs.

Infection and immunity·2026
Same author

Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.

EBioMedicine·2026
Same author

COMP-PMEPA1 axis promotes epithelial-to-mesenchymal transition in breast cancer cells.

Molecular oncology·2026
Same author

C4BP occludes the non-opsonic interaction of <i>Neisseria gonorrhoeae</i> with human neutrophil CEACAMs.

bioRxiv : the preprint server for biology·2026
Same author

Nuclear cell-free DNA on the loose: an early warning signal of ischemia-reperfusion injury in kidney transplantation.

Frontiers in immunology·2026
Same journal

Neoadjuvant and adjuvant therapy in uveal melanoma: toward systemic control of a systemic disease.

Cancer treatment reviews·2026
Same journal

Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective.

Cancer treatment reviews·2026
Same journal

Treatment of breast cancer brain metastases in the era of novel drugs.

Cancer treatment reviews·2026
Same journal

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.

Cancer treatment reviews·2026
Same journal

Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancer.

Cancer treatment reviews·2026
Same journal

Beyond body surface area: CT-derived body composition as a predictor of chemotherapy toxicity and survival in pancreatic ductal adenocarcinoma: a systematic review.

Cancer treatment reviews·2026
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

New perspectives on complement mediated immunotherapy.

Grzegorz Stasiłojć1, Anders Österborg2, Anna M Blom3

  • 1Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology UG-MUG, Medical University of Gdańsk, Dębinki 1 Street, 80210 Gdańsk, Poland.

Cancer Treatment Reviews
|March 20, 2016
PubMed
Summary
This summary is machine-generated.

Tumor-specific monoclonal antibodies (mAbs) can kill cancer cells via immune responses, but tumors evade these attacks. New research identifies factors limiting mAb effectiveness for better cancer immunotherapies.

Keywords:
CD20Complement systemImmunotherapy

More Related Videos

Depletion of Specific Cell Populations by Complement Depletion
06:17

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

22.8K
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.8K

Related Experiment Videos

Last Updated: Mar 24, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Depletion of Specific Cell Populations by Complement Depletion
06:17

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

22.8K
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.8K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Tumor-specific monoclonal antibodies (mAbs) leverage host immune effector functions for cancer cell killing.
  • Clinically approved anti-cancer mAbs primarily rely on innate immune mechanisms like complement activation and antibody-dependent cellular cytotoxicity (ADCC).
  • Tumor cells have evolved resistance strategies, including complement inhibition and epitope masking, to evade mAb-mediated immune attack.

Purpose of the Study:

  • To discuss newly identified limiting factors in monoclonal antibody (mAb) cancer immunotherapy.
  • To present novel mechanistic data on complement activation by antitumor antibodies.
  • To guide the development of next-generation immunotherapeutics.

Main Methods:

  • Review of existing literature on monoclonal antibody (mAb) mechanisms in cancer.
  • Analysis of tumor cell evasion strategies against mAb-mediated immunity.
  • Discussion of immune effector cell depletion and its impact on therapy efficacy.

Main Results:

  • Monoclonal antibodies (mAbs) utilize diverse immune effector mechanisms for tumor cell elimination.
  • Tumor cells employ multiple strategies to resist mAb-induced immune attack, leading to therapeutic resistance.
  • Depletion of immune effectors during treatment limits the efficacy of subsequent therapy rounds.

Conclusions:

  • Understanding tumor evasion tactics and immune effector dynamics is crucial for improving anti-cancer mAb therapies.
  • Novel mechanistic insights into complement activation by antitumor antibodies are key for future drug development.
  • Addressing limiting factors will enable the design of more effective next-generation immunotherapeutics.